News Image

NASDAQ:IART is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.

By Mill Chart

Last update: May 8, 2024

Our stock screener has singled out INTEGRA LIFESCIENCES HOLDING (NASDAQ:IART) as a stellar value proposition. NASDAQ:IART not only scores well in profitability, solvency, and liquidity but also maintains a very reasonable price point. We'll explore this further.

Valuation Insights: NASDAQ:IART

ChartMill provides a Valuation Rating to every stock, ranging from 0 to 10. This rating assesses various valuation aspects, comparing price to earnings and cash flows, while considering factors like profitability and growth. NASDAQ:IART boasts a 8 out of 10:

  • Based on the Price/Earnings ratio of 8.09, the valuation of IART can be described as reasonable.
  • Based on the Price/Earnings ratio, IART is valued cheaply inside the industry as 98.44% of the companies are valued more expensively.
  • IART's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 28.11.
  • The Price/Forward Earnings ratio is 7.70, which indicates a rather cheap valuation of IART.
  • Based on the Price/Forward Earnings ratio, IART is valued cheaply inside the industry as 98.44% of the companies are valued more expensively.
  • IART is valuated cheaply when we compare the Price/Forward Earnings ratio to 20.39, which is the current average of the S&P500 Index.
  • Based on the Enterprise Value to EBITDA ratio, IART is valued cheaply inside the industry as 96.35% of the companies are valued more expensively.
  • IART's Price/Free Cash Flow ratio is rather cheap when compared to the industry. IART is cheaper than 87.50% of the companies in the same industry.
  • The decent profitability rating of IART may justify a higher PE ratio.

Profitability Insights: NASDAQ:IART

ChartMill assigns a proprietary Profitability Rating to each stock. The score is computed by evaluating various profitability ratios and margins and ranges from 0 to 10. NASDAQ:IART was assigned a score of 7 for profitability:

  • IART has a better Return On Assets (1.79%) than 73.96% of its industry peers.
  • IART's Return On Equity of 4.27% is fine compared to the rest of the industry. IART outperforms 75.52% of its industry peers.
  • IART has a better Return On Invested Capital (6.57%) than 82.81% of its industry peers.
  • IART has a Profit Margin of 4.39%. This is in the better half of the industry: IART outperforms 75.00% of its industry peers.
  • IART has a Operating Margin of 17.63%. This is amongst the best in the industry. IART outperforms 91.15% of its industry peers.
  • In the last couple of years the Operating Margin of IART has grown nicely.
  • IART has a better Gross Margin (63.09%) than 61.98% of its industry peers.

ChartMill's Evaluation of Health

ChartMill assigns a Health Rating to every stock. This score ranges from 0 to 10 and evaluates the different health aspects like liquidity and solvency, both absolutely, but also relative to the industry peers. NASDAQ:IART scores a 5 out of 10:

  • The Debt to FCF ratio of IART (20.52) is better than 72.40% of its industry peers.
  • A Current Ratio of 3.45 indicates that IART has no problem at all paying its short term obligations.
  • A Quick Ratio of 2.18 indicates that IART has no problem at all paying its short term obligations.

Exploring NASDAQ:IART's Growth

Every stock receives a Growth Rating from ChartMill, ranging from 0 to 10. This rating assesses various growth aspects, including historical and projected EPS and revenue growth. NASDAQ:IART boasts a 4 out of 10:

  • Based on estimates for the next years, IART will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.76% on average per year.
  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

Our Decent Value screener lists more Decent Value stocks and is updated daily.

Check the latest full fundamental report of IART for a complete fundamental analysis.

Keep in mind

This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.

Back

INTEGRA LIFESCIENCES HOLDING

NASDAQ:IART (5/17/2024, 7:05:03 PM)

After market: 27.54 0 (0%)

27.54

+0.05 (+0.18%)

IART News

News Image2 days ago - Market News VideoIART July 19th Options Begin Trading
News Image6 days ago - Integra LifeSciences Holdings CorporationIntegra LifeSciences to Present at the 2024 Bank of America Healthcare Conference

PRINCETON, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company,...

News Image11 days ago - ChartmillNASDAQ:IART is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.

Investors should take notice ofINTEGRA LIFESCIENCES HOLDING (NASDAQ:IART)—it offers a great deal for the fundamentals it presents.

News Image13 days ago - ChartmillHere are the top movers in Monday's session, showcasing the stocks with significant price changes.

Which stocks are moving on Monday?

News Image13 days ago - ChartmillTop movers in Monday's session

Intrigued by the market activity in the middle of the day on Monday? Uncover the key winners and losers of today's session in our insightful analysis.

News Image13 days ago - InvestorPlaceIART Stock Earnings: Integra Lifesciences Meets EPS, Beats Revenue for Q1 2024

IART stock results show that Integra Lifesciences met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.

News Image13 days ago - ChartmillGapping stocks in Monday's session

The market is buzzing with gapping stocks on Monday. Let's uncover which stocks are experiencing notable gaps during today's session.

News Image13 days ago - Integra LifeSciences Holdings CorporationIntegra LifeSciences Reports First Quarter 2024 Financial Results

PRINCETON, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company,...

News Image19 days ago - Integra LifeSciences Holdings CorporationIntegra LifeSciences to Spotlight CereLink® Intracranial Pressure (ICP) Monitoring System at the American Association of Neurological Surgeons (AANS) Annual Scientific Meeting

The Integra LifeSciences' CereLink ICP Monitoring System will be highlighted in booth #655 at AANS Annual Meeting in Chicago, Illinois....

News Imagea month ago - Market News VideoFirst Week of December 20th Options Trading For Integra LifeSciences Holdings (IART)
News Imagea month ago - Integra LifeSciences Holdings CorporationIntegra LifeSciences to Reschedule the First Quarter 2024 Financial Results Conference Call to May 6, 2024

PRINCETON, N.J., April 18, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology...

News Imagea month ago - Market News VideoIntegra LifeSciences Holdings Enters Oversold Territory (IART)
IART Links
Follow us for more